Bisubstrate fluorescent probes and biosensors in binding assays for HTS of protein kinase inhibitors

Biochimica et Biophysica Acta - Proteins and Proteomics

Volumn 1804, Issue 3, 2010, Pages 541-546

  Uri, Asko ^a   Lust, Marje ^a   Vaasa, Angela ^a   Lavogina, Darja ^a   Viht, Kaido ^a   Enkvist, Erki ^a  

^a UNIVERSITY OF TARTU   (Estonia)

Author keywords

ARC; Binding assay; Biosensor; Bisubstrate inhibitor; Fluorescence anisotropy; Fluorescence polarization; Fluorescent probe; FRET; HTS; Protein kinase; SPR

Indexed keywords

ADENOSINE; DEXTRO ARGININE; FLUORESCENT DYE; PROTEIN; PROTEIN KINASE INHIBITOR;

BINDING AFFINITY; BINDING ASSAY; BINDING SITE; BIOSENSOR; CELL MEMBRANE; FLUORESCENCE RESONANCE ENERGY TRANSFER; HIGH THROUGHPUT SCREENING; PRIORITY JOURNAL; REVIEW;

ANIMALS; BIOSENSING TECHNIQUES; DRUG EVALUATION, PRECLINICAL; FLUORESCENCE RESONANCE ENERGY TRANSFER; FLUORESCENT DYES; HUMANS; PEPTIDES; PROTEIN ARRAY ANALYSIS; PROTEIN BINDING; PROTEIN KINASE INHIBITORS; PROTEIN KINASES;

EID: 75349090404     PISSN: 15709639     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bbapap.2009.10.019     Document Type: Review

References (33)

1. Cohen P. Protein kinases: the major drug targets of the twenty-first century?. Nat. Rev., Drug Discov. 1 (2002) 309-315
2. Olive D.M. Quantitative methods for the analysis of protein phosphorylation in drug development. Expert Rev. Proteomics 1 (2004) 327-341
3. Jia Y., Quinn C.M., Kwak S., and Talanian R.V. Current in vitro kinase assay technologies: the quest for a universal format. Curr. Drug Discov. Technol. 5 (2008) 59-69
4. Yang J., Copeland R.A., and Lai Z. Defining balanced conditions for inhibitor screening assays that target bisubstrate enzymes. J. Biomol. Screen. 14 (2009) 111-120
5. Vainshtein I., Silveria S., Kaul P., Rouhani R., Eglen R.M., Wang J., and high-throughput A. nonisotopic, competitive binding assay for kinases using nonselective inhibitor probes (ED-NSIP). J. Biomol. Screen 7 (2002) 507-514
6. Lebakken C.S., Kang H.C., and Vogel K.W. A fluorescence lifetime based binding assay to characterize kinase inhibitors. J. Biomol. Screen. 12 (2007) 828-841
7. Karaman M.W., Herrgard S., Treiber D.K., Gallant P., Atteridge C.E., Campbell B.T., Chan K.W., Ciceri P., Davis M.I., Edeen P.T., Faraoni R., Floyd M., Hunt J.P., Lockhart D.J., Milanov Z.V., Morrison M.J., Pallares G., Patel H.K., Pritchard S., Wodicka L.M., and Zarrinkar P.P. A quantitative analysis of kinase inhibitor selectivity. Nat. Biotechnol. 26 (2008) 127-132
8. Lebakken C.S., Riddle S.M., Singh U., Frazee W.J., Eliason H.C., Gao Y., Reichling L.J., Marks B.D., and Vogel K.W. Development and applications of a broad-Coverage, TR-FRET-based kinase binding assay platform. J. Biomol. Screen. 14 (2009) 924-935
9. Iyer G.H., Taslimi P., and Pazhanisamy S. Staurosporine-based binding assay for testing the affinity of compounds to protein kinases. Anal. Biochem. 373 (2008) 197-206
10. M.J. Brown, Novel fluorescent kinase ligands and assays employing the same, WO 2008/071937 (2008).
11. Owicki J.C. Fluorescence polarization and anisotropy in high throughput screening: perspectives and primer. J. Biomol. Screen. 5 (2000) 297-306
12. Huang X. Fluorescence polarization competition assay: the range of resolvable inhibitor potency is limited by the affinity of the fluorescent ligand. J. Biomol. Screen. 8 (2003) 34-38
13. Roehrl M.H., Wang J.Y., and Wagner G. A general framework for development and data analysis of competitive high-throughput screens for small-molecule inhibitors of protein-protein interactions by fluorescence polarization. Biochemistry 43 (2004) 16056-16066
14. Vogel K.W., Marks B.D., Kupcho K.R., Vedvik K.L., and Hallis T.M. Facile conversion of FP to TR-FRET assays using terbium chelates: nuclear receptor competitive binding assays as examples. Lett. Drug Design Discov. 5 (2008) 416-422
15. Li Y., Xie W., and Fang G. Fluorescence detection techniques for protein kinase assay. Anal. Bioanal. Chem. 390 (2008) 2049-2057
16. Montgomery C.P., Murray B.S., New E.J., Pal R., and Parker D. Cell-penetrating metal complex optical probes: targeted and responsive systems based on lanthanide luminescence. Acc. Chem. Res. 42 (2009) 925-937
17. Loog M., Uri A., Raidaru G., Järv J., and Ek P. Adenosine-5′-carboxylic acid peptidyl derivatives as inhibitors of protein kinases. Bioorg. Med. Chem. Lett. 9 (1999) 1447-1452
18. Lavogina D., Enkvist E., and Uri A. Bisubstrate inhibitors of protein kinases: from principle to practical applications. Chem. Med. Chem. 5 (2010) 23-34
19. Lavogina D., Lust M., Viil I., König N., Raidaru G., Rogozina J., Enkvist E., Uri A., and Bossemeyer D. Structural analysis of ARC-type inhibitor (ARC-1034) binding to protein kinase A catalytic subunit and rational design of bisubstrate analogue inhibitors of basophilic protein kinases. J. Med. Chem. 52 (2009) 308-321
20. Uri A., Raidaru G., Subbi J., Padari K., and Pooga M. Identification of the ability of highly charged nanomolar inhibitors of protein kinases to cross plasma membranes and carry a protein into cells. Bioorg. Med. Chem. Lett. 12 (2002) 2117-2120
21. Viht K., Padari K., Raidaru G., Subbi J., Tammiste I., Pooga M., and Uri A. Liquid-phase synthesis of a pegylated adenosine-oligoarginine conjugate, cell-permeable inhibitor of cAMP-dependent protein kinase. Bioorg. Med. Chem. Lett. 13 (2003) 3035-3039
22. Enkvist E., Lavogina D., Raidaru G., Vaasa A., Viil I., Lust M., Viht K., and Uri A. Conjugation of adenosine and hexa-(d-arginine) leads to a nanomolar bisubstrate-analog inhibitor of basophilic protein kinases. J. Med. Chem. 49 (2006) 7150-7159
23. Vaasa A., Viil I., Enkvist E., Viht K., Raidaru G., Lavogina D., and Uri A. High-affinity bisubstrate probe for fluorescence anisotropy binding/displacement assays with protein kinases PKA and ROCK. Anal. Biochem. 385 (2009) 85-93
24. Viht K., Schweinsberg S., Lust M., Vaasa A., Raidaru G., Lavogina D., Uri A., and Herberg F.W. Surface-plasmon-resonance-based biosensor with immobilized bisubstrate analog inhibitor for the determination of affinities of ATP- and protein-competitive ligands of cAMP-dependent protein kinase. Anal. Biochem. 362 (2007) 268-277
25. Enkvist E., Raidaru G., Vaasa A., Pehk T., Lavogina D., and Uri A. Carbocyclic 3′-deoxyadenosine-based highly potent bisubstrate-analog inhibitor of basophilic protein kinases. Bioorg. Med. Chem. Lett. 17 (2007) 5336-5339
26. Enkvist E., Kriisa M., Roben M., Kadak G., Raidaru G., and Uri A. Effect of the structure of adenosine mimic of bisubstrate-analog inhibitors on their activity towards basophilic protein kinases. Bioorg. Med. Chem. Lett. 19 (2009) 6098-6101
27. Copeland R.A. Evaluation of Enzyme Inhibitors in Drug Discovery: A Guide for Medicinal Chemists and Pharmacologists (2005), John Wiley & Sons, Inc., New Jersey 178-213
28. Mathis G. Probing molecular interactions with homogeneous techniques based on rare earth cryptates and fluorescence energy transfer. Clin. Chem. 41 (1995) 1391-1397
29. Starkuviene V., and Pepperkok R. The potential of high-content high-throughput microscopy in drug discovery. Br. J. Pharmacol. 152 (2007) 62-71
30. Vaasa A., Lust M., Uri A., and Zaccolo M. Cellular imaging of membranepermeable bisubstrate-analogue inhibitors of protein kinases. Acta Biochim. Pol. 56 Supplement 1 (2009) 63
31. Lissandron V., Terrin A., Collini M., D'alfonso L., Chirico G., Pantano S., and Zaccolo M. Improvement of a FRET-based indicator for cAMP by linker design and stabilization of donor-acceptor interaction. J. Mol. Biol. 354 (2005) 546-555
32. Adams S.R., Harootunian A.T., Buechler Y.J., Taylor S.S., and Tsien R.Y. Fluorescence ratio imaging of cyclic AMP in single cells. Nature 349 (1991) 694-697
33. Zaccolo M., De Giorgi F., Cho C.Y., Feng L., Knapp T., Negulescu P.A., Taylor S.S., Tsien R.Y., and Pozzan T. A genetically encoded, fluorescent indicator for cyclic AMP in living cells. Nat. Cell Biol. 2 (2000) 25-29